ALZN Alzamend Neuro, Inc.
USHealthcareAs of 2026-08-24
Why ALZN matters now
Alzamend Neuro, Inc. (ALZN) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.55 with -0.64% on the session and $5.9M in market capitalization; recent performance reads 1-month +20.79% and YTD -32.97%.
The latest financial table shown here is Q3 2026, with revenue of $0.00, net income of $-2.2M, and EPS of $-0.58. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -161.0%.
The latest indexable market news headline is "Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes AULT MILTON C III filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.12
P/S
0.00
EV/EBITDA
-0.16
DCF Value
$7.42
FCF Yield
-161.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-177.5%
ROA
-174.2%
ROIC
-322.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $0.00 | $-2.2M | $-0.58 |
| Q2 2026 | $0.00 | $-1.0M | $-0.30 |
| Q1 2026 | $0.00 | $-2.7M | $-1.28 |
| Q4 2025 | $0.00 | $-1.1M | $-2.43 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.17
Alzamend Neuro, Inc. is an early clinical-stage biopharmaceutical firm dedicated to advancing therapeutic solutions for neurodegenerative and psychiatric illnesses. Its development pipeline features two key candidates. AL001, currently in Phase II clinical trials, administers a proprietary blend of lithium, proline, and salicylate. This compound is designed to address a broad spectrum of conditions such as Alzheimer's, bipolar disorder, post-traumatic stress disorder (PTSD), major depressive disorder (MDD), and other neurodegenerative or psychiatric conditions. Also in its portfolio is AL002, which has successfully completed its preclinical phase. AL002 represents a cell-based therapeutic vaccine strategy, employing mutant-peptide sensitized cells to restore and enhance a patient's immune system in its fight against Alzheimer's disease. Incorporated in 2016, Alzamend Neuro, Inc. maintains its headquarters in Atlanta, Georgia.